DisCoVisc Comparative Evaluation

PHASE3CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 29, 2008

Conditions
Cataracts
Interventions
DEVICE

DisCoVisc

DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

DEVICE

DuoVisc

DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

DEVICE

BioVisc

BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

DEVICE

Healon5

Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

DEVICE

Amvisc Plus

Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

Trial Locations (1)

76134

Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00732225 - DisCoVisc Comparative Evaluation | Biotech Hunter | Biotech Hunter